![]() ![]() Novamind has a tight structure with only 42 million shares outstanding and a high insider ownership of 40%. These are very large purchases by insiders of Novamind and we believe this should not be overlooked as we head into 2022. Jesse Kaplan has also purchased a total of 352,500 shares for the month of December bringing his total just over 2.4 million shares. ![]() Novamind also boasts an impressive list of research partners which includes Merck, Janssen (Owned by Johnson & Johnson), The university of Utah, The University of Texas in Austin, Karuna Therapeutics, Syneos Health and more.Īlso something very noteworthy for investors is the fact that insiders of the company have been purchasing stock and quite a lot of it! The company’s CEO Yaron Conforti purchased 96,600 shares in the month of December, and currently holds over 3.4 million shares. According to the company’s corporate presentation, NM ’s subsidiary has received over 20,000 visits at its clinics in 2020 and has administered more than 7,000 ketamine therapy treatments and 5,000 doses of Spravato™, an FDA approved formulation of ketamine for the use in adults with treatment resistant depression (TRD) and acute suicidal ideation. This acquisition is set to be completed in early 2022, and will be a catalyst that may propel the stock to higher levels. In mid-November, Novamind announced that it intends to acquire two mental health clinics under the “Foundations for Change” brand in the state of Arizona through a Letter of Intent which it recently signed. The company also has a healthy $5.9 Million in Cash with no long-term debts! As of its last financial statement reported on November 29 th 2021, NM posted revenues of $1.8 Million for its third quarter ending September 31 st 2021. As of this write up, through its subsidiary Cedar Psychiatry Inc., Novamind has 6 clinics that are operational with 4 more sites set to open up in 2022.įor such an early-stage company in a new industry, we’re impressed to see Novamind is already generating revenue. Novamind ( CSE: NM ) ( OTCQB: NVMDF ) operates a growing network of psychiatric clinics and research sites specializing in ketamine assisted psychotherapy for those suffering from mental illnesses such as PTSD, Suicide Ideation anxiety and depression. ![]() These 3 stocks have a strong management teams, ideal share structure, cash on the books and no debt! In today’s article we’ll go over 3 of the top psychedelic stocks we believe are undervalued and a must watch for 2022 as we expect a resurgence of the psychedelic sector. With the rise in popculture around alternative medicines and therapies in recent years, especially in affluent and tech inclined communities, we are in presence of a new era of development of therapeutics and hopeful solutions that is beginning to drive a resurgence in psychedelics and psychedelic therapies to assist those suffering with mental health and addiction. During that same period, victims and those who suffer any of multiple forms of addiction whether it is opioids, tobacco, alcohol or other substances, have had little to no advancement for the cure of their diseases. Pharmaceuticals such as Oxycontin have led to substance abuse and opioid addiction. As an example of worst, most people are familiar with the tragedy that is Oxycontin and the lawsuits surrounding Purdue Pharma, the maker of the notorious painkiller which lead to the company pleading guilty to criminal charges resulting in a settlement of $8 Billion. For over a century, the pharmaceutical industry has seen an tremendous amount of growth through breakthrough R&D, patents and mass distribution of its pharmaceuticals to millions of people around the world for both better and worst. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |